Benitec Biopharma (NASDAQ:BNTC – Get Free Report) and NexImmune (NASDAQ:NEXI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.
Risk and Volatility
Benitec Biopharma has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for Benitec Biopharma and NexImmune, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Benitec Biopharma | 0 | 0 | 7 | 2 | 3.22 |
| NexImmune | 0 | 0 | 0 | 0 | 0.00 |
Valuation & Earnings
This table compares Benitec Biopharma and NexImmune”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Benitec Biopharma | $80,000.00 | 3,092.60 | -$21.75 million | ($1.51) | -6.99 |
| NexImmune | N/A | N/A | -$32.34 million | ($18.54) | -0.01 |
Benitec Biopharma has higher revenue and earnings than NexImmune. Benitec Biopharma is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 9.9% of NexImmune shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 14.9% of NexImmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Benitec Biopharma and NexImmune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Benitec Biopharma | N/A | -44.61% | -41.25% |
| NexImmune | N/A | -534.32% | -213.72% |
Summary
Benitec Biopharma beats NexImmune on 10 of the 13 factors compared between the two stocks.
About Benitec Biopharma
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
About NexImmune
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
